Jasper Therapeutics cuts workforce ~50%, halts non-urticaria programs; CMO departs

Jasper Therapeutics, Inc.

Workforce reduction of ~50% and halting of all non-chronic urticaria programs.
Estimated $1.8M-$2.2M in severance cash expenditures through Q3 2025.
CMO Edwin Tucker departs effective Aug 1, 2025; receives 12 months base salary and COBRA.
Dr. Daniel Adelman appointed Acting Chief Medical Officer effective Aug 1, 2025.
Focus on briquilimab in CSU/CIndU; data from BEACON/SPOTLIGHT expected later this year.

item 2.05item 5.02item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.